Literature DB >> 24780002

The ins and outs of fibroblast growth factor receptor signalling.

Stacey J Coleman1, Charo Bruce1, Athina-Myrto Chioni1, Hemant M Kocher, Richard P Grose1.   

Abstract

FGFR (fibroblast growth factor receptor) signalling plays critical roles in embryogensis, adult physiology, tissue repair and many pathologies. Of particular interest over recent years, it has been implicated in a wide range of cancers, and concerted efforts are underway to target different aspects of FGFR signalling networks. A major focus has been identifying the canonical downstream signalling pathways in cancer cells, and these are now relatively well understood. In the present review, we focus on two distinct but emerging hot topics in FGF biology: its role in stromal cross-talk during cancer progression and the potential roles of FGFR signalling in the nucleus. These neglected areas are proving to be of great interest clinically and are intimately linked, at least in pancreatic cancer. The importance of the stroma in cancer is well accepted, both as a conduit/barrier for treatment and as a target in its own right. Nuclear receptors are less acknowledged as targets, largely due to historical scepticism as to their existence or importance. However, increasing evidence from across the receptor tyrosine kinase field is now strong enough to make the study of nuclear growth factor receptors a major area of interest.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24780002     DOI: 10.1042/CS20140100

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  19 in total

Review 1.  A nuclear odyssey: fibroblast growth factor-2 (FGF-2) as a regulator of nuclear homeostasis in the nervous system.

Authors:  Benjamin Förthmann; Claudia Grothe; Peter Claus
Journal:  Cell Mol Life Sci       Date:  2015-01-01       Impact factor: 9.261

Review 2.  2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology.

Authors:  Richard J Epstein; Li Jun Tian; Yan Fei Gu
Journal:  J Oncol       Date:  2021-04-30       Impact factor: 4.375

Review 3.  Fibroblast Growth Factor Signalling in the Diseased Nervous System.

Authors:  Lars Klimaschewski; Peter Claus
Journal:  Mol Neurobiol       Date:  2021-04-15       Impact factor: 5.590

Review 4.  The Fibroblast Growth Factor signaling pathway.

Authors:  David M Ornitz; Nobuyuki Itoh
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-03-13       Impact factor: 5.814

Review 5.  Alternative RNA structure-coupled gene regulations in tumorigenesis.

Authors:  Feng-Chi Chen
Journal:  Int J Mol Sci       Date:  2014-12-29       Impact factor: 5.923

Review 6.  Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases.

Authors:  Masaru Katoh
Journal:  Front Cell Dev Biol       Date:  2014-10-16

Review 7.  FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).

Authors:  Masaru Katoh
Journal:  Int J Mol Med       Date:  2016-05-31       Impact factor: 4.101

Review 8.  Negative Regulation of FGFR (Fibroblast Growth Factor Receptor) Signaling.

Authors:  Patrycja Szybowska; Michal Kostas; Jørgen Wesche; Ellen Margrethe Haugsten; Antoni Wiedlocha
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

9.  Fibroblast growth factors as tissue repair and regeneration therapeutics.

Authors:  Quentin M Nunes; Yong Li; Changye Sun; Tarja K Kinnunen; David G Fernig
Journal:  PeerJ       Date:  2016-01-12       Impact factor: 2.984

10.  Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression.

Authors:  Bernhard Englinger; Daniela Lötsch; Christine Pirker; Thomas Mohr; Sushilla van Schoonhoven; Bernd Boidol; Charles-Hugues Lardeau; Melanie Spitzwieser; Pál Szabó; Petra Heffeter; Irene Lang; Margit Cichna-Markl; Bettina Grasl-Kraupp; Brigitte Marian; Michael Grusch; Stefan Kubicek; Gergely Szakács; Walter Berger
Journal:  Oncotarget       Date:  2016-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.